RARE
Ultragenyx Pharmaceutical Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.73
+5.93%Margins
Gross margin
83.1%
EBITDA margin
-66.0%
EBIT margin
-73.8%
Net margin
-81.8%
FCF margin
-68.3%
201.5%
Return on equity
-46.4%
Return on assets
-58.1%
Return on invested capital
0.56x
Asset turnover
-$485.3M
Cash from operations
$2.96
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026